Table 1.
Patients detailed data (clinical and radiological manifestation, serum marker, and cancer antigen alterations) before and after PECT.
| Patient ID | PECT site | Target lesion | Clinical manifestation changes | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinic (measured circumference) | Clinic (% of changes) | Radiology | Radiology (% of changes) | Serum markers | Serum marker (% of changes) | ||||||
| 30 days before PECT to Day 0 | Day 0 to After PECT | 30 days before PECT to Day 0 | Day 0 to After PECT | 30 days before PECT to Day 0 | Day 0 to After PECT | ||||||
| 8 | Both Lung Lobes | Not measurable | Most Prominent Lung Nodule | Increasing in size and number of lung nodules | Completely vanish | ESR | 55% | −86% | -No clinical changes | ||
| 14 | Left Breast | Not measurable | Left breast 7 O’clock mass | 128% | −57% | ESR | 100% | −57% | -Significant reduction in pain and edema of the left breast -Improvement of anorexia, general weakness, and sleeping condition |
||
| Left breast Lower Inner Quadrant mass | 57% | −54% | LDH | 38% | −39% | ||||||
| Left breast Upper Outer Quadrant mass | 47% | −34% | |||||||||
| 13 | Epigastric Wall | Epigastric wall mass | 0% | −10% | Epigastric wall mass | 34% | −26% | CA125 | 7% | −17% | -Healing of hysterectomy wound -Significant reduction of ki67 from 30 to 3 -Significant reduction in pain of epigastric wall mass -Improvement of anorexia, general weakness, and sleeping condition |
| 5 | Liver | Abdominal circumference | 5% | −6% | Left liver lobe mass1 | 62.5% | −100% | PSA | 35% | −19% | -Healing of the abdominal pain -Improvement of defecation condition -Reduction in abdominal circumference (amount of ascites) -Improvement of anorexia, general weakness, and sleeping condition |
| Left liver lobe mass2 | 17% | −100% | AST | 239% | −40% | ||||||
| ALT | 30% | 25% | |||||||||
| Caudate liver lobe mass | 52% | −29% | ALP | 206% | 10% | ||||||
| y-GT | 46% | 10% | |||||||||
| 1 | Left Breast and left axillary | Left wrist | 11% | −11% | Left breast 12 O’clock mass | 33% | −52% | CA125 | 8% | 7% | -Healing of the breast and upper limb pain -Significant reduction of left upper limb and breast edema -Decreasing adhesion of tumor and ability to do the mastectomy -Improvement of anorexia, general weakness, and sleeping condition |
| Left elbow | 30% | −13% | |||||||||
| Left arm | 19% | −17% | Left breast Axillary mass1 | 6% | −23% | CA15-3 | 9% | −35% | |||
| Right wrist | 1% | −5% | |||||||||
| Right elbow | 3% | −5% | Left breast Axillary mass2 | 7% | −49% | CEA | 22% | −38% | |||
| Right arm | 2% | −4% | Left breast Upper Outer Quadrant mass | 28% | −35% | ||||||
| 9 | The wound of right upper back | Wound area on the skin of the right upper back | 100% | ~ − 90% | No mass | CA125 | 44% | −31% | -Significant reduction in pain of ulcers -Ability to sleep supine (on the wound) -Healing of the wound and decrease in wound area -Improvement of anorexia, general weakness, and sleeping condition |
||
| CA15-3 | 17% | −37% | |||||||||
| CEA | 57% | −6% | |||||||||
| 4 | Liver | Abdominal circumference | 2% | −5% | Segment 7 liver mass | 83% | −25% | CA125 | 46% | −11% | -Significant reduction in abdominal pain -Reduction in abdominal circumference (amount of ascites) -Improvement of anorexia, general weakness, and sleeping condition |
| Segment 7 liver mass | 13% | −3% | CA15-3 | 95% | −8% | ||||||
| CEA | 492% | −6% | |||||||||
| 26 | Liver | Not measurable | Right liver lobe mass | 36% | −32% | CA125 | 231% | 104% | -Abdominal and lower back pain reduction -Improvement of anorexia, general weakness and sleeping condition |
||
| CA15-3 | 87% | 32% | |||||||||
| CEA | 244% | 32% | |||||||||
| AST | 141% | 37% | |||||||||
| Left liver lobe mass | 383% | −48% | ALT | 75% | 22% | ||||||
| ALP | 85% | 16% | |||||||||
| y-GT | 120% | 51% | |||||||||
| 3 | Right Breast | Not measurable | Right Retro areolar mass | 10% | −78% | CA125 | 492% | 116% | -Right breast pain reduction -Right breast stiffness and edema reduction -Decreasing in size and number of breast subcutaneous nodules and masses -Improvement of anorexia, general weakness, and sleeping condition |
||
| Right breast 9 O’clock mass | 6% | −68% | CA15-3 | 11% | 0.6% | ||||||
| Right breast 10 O’clock mass | 5% | −20% | CEA | 22% | 66% | ||||||
| Right breast 9-10 mm far zone mass | 7% | −66% | |||||||||
| 27 | Liver | Not measurable | Left liver lobe mass | 53% | −48% | CA125 | 103% | 46% | -Capable to walk -Abdominal pain reduction -Improvement of anorexia, general weakness, and sleeping condition |
||
| Right liver lobe mass | 18% | −15% | CA15-3 | 39% | −75% | ||||||
| LAP posterior IVC mass | 33% | −45% | CEA | 0% | 33% | ||||||
| LAP portahepatis 1 mass | 27% | −25% | AST | 52% | 34% | ||||||
| LAP portahepatis 2 mass | 21% | −6% | ALT | 46% | −41% | ||||||
| LAP portahepatis 3 mass | 23% | −18% | ALP | 39% | 36% | ||||||
| y-GT | 148% | 82% | |||||||||
| 28 | Wound of Right Breast (site of mastectomy) | No mass | No mass | CA125 | 7% | −14% | -Complete healing of the breast pain -Significant healing of the right mastectomy site wound |
||||
| CA15 − 3 | 2% | −3% | |||||||||
| CEA | 0% | −19% | |||||||||
| ESR | 46% | −50% | |||||||||
| CRP | 75% | > −43% | |||||||||
| 20 | Neck | Not measurable | Neck lymphadenopathy | 10% | −16% | Thyroglobulin | 10% | −22% | -Improvement of hoarseness -Improvement of swallowing condition |
||
| 7 | Neck and lung | Not measurable | Neck lymphadenopathy | 190% | −77% | AntiThyroglobulin | 39% | −15% | -Decreasing neck mass size -Improvement of hoarseness -Improvement of swallowing condition |
||
| 2 | Left Breast | Not measurable | Left Breast Axillary tail mass | 50% | −48% | CA125 | 25% | −39% | Stiffness, edema, pain, and size of left breast reduction | ||
| Left Breast Lateral part mass | 8% | −46% | |||||||||
| Left Breast UOQ mass | 117% | −63% | CA15-3 | 31% | −35% | ||||||
| Left Breast UIQ mass | 49% | −86% | CEA | 2% | −25% | ||||||
| Left Breast 6 O’clock mass | 25% | 62% | |||||||||
| 6 | Liver | Abdominal circumference | 7% | −5% | Spleen Volume | 5% | −21% | CA19-9 | 16% | −24% | -Volume reduction of the splenomegaly -Improvement of anorexia, general weakness, and sleeping condition |
| Gallbladder Size | 15% | −25% | CEA | 46% | −26% | ||||||
| Most prominent liver Mass | 10% | −3% | AST | 48% | −18% | ||||||
| Segment 8 liver mass | Because of the liver heterogeneity tumor was not obvious | −25% | ALT | 40% | −9% | ||||||
| Right liver lobe mass | Because of the liver heterogeneity tumor was not obvious | −100% | ALP | 29% | −23% | ||||||
| y-GT | 9% | −13% | |||||||||
| 22 | Skin of right breast | No mass | No mass | CA125 | 31% | 19% | -Breast pain reduction -Skin erythema reduction |
||||
| CA15-3 | 9% | 7% | |||||||||
| CEA | 17% | 40% | |||||||||
| 12 | Epigastric region | mass circumference in physical examination | 25% | −30% | Epigastric mass | 66% | −100% | CA19-9 | 30% | −34% | -Epigastric pain and stiffness of epigastric area reduction -Improvement of anorexia, general weakness, and sleeping condition |
| CEA | 91% | −39% | |||||||||
| 40 | Liver | Not measurable | Segment 5 liver mass | 58% | 0% | CA19-9 | 21% | −7% | -Abdominal pain healing -Improvement of anorexia, general weakness, sleeping condition |
||
| Segment 8 liver mass | 166% | 0% | CEA | 22% | 2% | ||||||
| Left liver lobe | 62% | −21% | AST | 32% | −25% | ||||||
| ALT | 0% | −20% | |||||||||
| Right liver lobe mass | 55% | 29% | ALP | 145% | −59% | ||||||
| y-GT | 59% | 1% | |||||||||
| 29 | Periumbilical | Not measurable | Abdominal right lower quadrant mass | 104% | −27% | CA125 | 58% | 41% | -Abdominal pain reduction -Improvement of anorexia, general weakness, and sleeping condition |
||
| CEA | 22% | 9% | |||||||||
| Right para umbilical mass | 37% | −20% | a-FP | 16% | 14% | ||||||
| HCG | 13% | −20% | |||||||||
| 24 | Periumbilical Region | Abdominal circumference | 8% | −1% | Liver mass | 28% | 25% | CEA | 92% | 6% | -Capable to walk -Abdominal pain reduction -Improvement of anorexia, general weakness, and sleeping condition |
| Spleen mass | 98% | 40% | CA19-9 | 194% | 13% | ||||||
| Periumbilical mass | 54% | −1% | AST | 92% | 111% | ||||||
| ALT | 62% | 53% | |||||||||
| Pelvic Cavity mass | 16% | −9% | ALP | 27% | −20% | ||||||
| y-GT | 35% | −6% | |||||||||
| 24 | Liver | Abdominal circumference | −1% | −3% | Liver mass | 25% | −9% | CEA | 6% | 6% | -Capable to walk -Abdominal pain reduction -Improvement of anorexia, general weakness, and sleeping condition |
| Spleen mass | 40% | −7% | CA19-9 | 13% | 5% | ||||||
| Periumbilical mass | −1% | 6% | AST | 111% | 33% | ||||||
| ALT | 53% | 40% | |||||||||
| Pelvic Cavity mass | −9% | 30% | ALP | −20% | −11% | ||||||
| y-GT | −6% | −4% | |||||||||
| 16 | Lungs | Not measurable | Lung nodules | Increasing | No significant change | ESR | 142% | 61% | -Improvement of cough -Improvement of dyspnea from FCIV to FCII -Improvement of anorexia, general weakness, and sleeping condition |
||
| CRP | 328% | 47% | |||||||||
| 33 | Left Flank | Not measurable | Excluded from the trial | CA125 | 50% | 36% | -Complete healing of flank pain -Improvement of anorexia, general weakness, and sleeping condition |
||||
| 37 | Liver | Not measurable | Segment 2 liver mass | 100% | −78% | CA125 | 28% | −67% | -Capable to walk -Improvement of anorexia, general weakness, and sleeping condition |
||
| CA19-9 | 30% | −31% | |||||||||
| AST | 12% | 6% | |||||||||
| ALT | 20% | −17% | |||||||||
| ALP | 15% | −20% | |||||||||
| y-GT | 40% | −36% | |||||||||
| ESR | 49% | −81% | |||||||||
| CRP | 24% | −83% | |||||||||
| 11 | Left and Right axilla | Left wrist | 20% | −37% | Excluded from the trial | Excluded from the trial | -Significant reduction in upper limbs pain -Significant reduction in upper limbs edema -Improvement of anorexia, general weakness, sleeping condition |
||||
| Left elbow | 24% | −18% | |||||||||
| Left arm | 18% | −17% | |||||||||
| Right wrist | 10% | −18% | |||||||||
| Right elbow | 17% | −20% | |||||||||
| Right arm | 12% | −14% | |||||||||
| 31 | Right groin and pubic area | Not measurable | Pelvic cavity mass | Increasing in size and developing new masses on the skin of the head, chest, etc. | stable | ESR | 48% | 1% | -Right groin pain reduction -Healing of the lower limbs paresthesia -Improvement of anorexia, general weakness, and sleeping condition |
||
| CRP | 75% | 46% | |||||||||
| 41 | Left breast | Not measurable | Left breast masses | Increasing in size and number | stable | CA125 | 20% | −10% | -Reduction in left breast pain and size -Improvement of anorexia, general weakness, and sleeping condition |
||
| CA15-3 | 67% | −12% | |||||||||
| CEA | 85% | 42% | |||||||||
| 19 | Left upper back | left upper back tumor | 90% | −49% | Just clinically measured | Excluded from the trial | -Capable to walk -Healing the pain of the upper back tumor -Decrease the size of the upper back tumor -Ability to sleep in the supine position on the tumor -Improvement of anorexia, general weakness, and sleeping condition |
||||
| 25 | Left breast and left upper back | No mass | No mass | Excluded from the trial | -Capable to walk -Significant reduction in pain of ulcers -Ability to sleep supine (on the wound) -Healing of the wound and decrease in wound area -Improvement of anorexia, general weakness, and sleeping condition |
||||||
| 10 | Frontal mass | Frontal mass | 242% | −86% | Just clinically measured | CA125 | 23% | −39% | -Decreasing frontal mass size -Improvement of anorexia, general weakness, and sleeping condition |
||
| 18 | Left breast mass | Left breast mass | 21% | −26% | Just clinically measured | CA125 | 43% | −11% | -Reduction in the left breast and breast mass pain -Reduction in size and edema of the left breast -Improvement of anorexia, general weakness, and sleeping condition |
||
| CA15-3 | 26% | −29% | |||||||||
| CEA | 4% | −5% | |||||||||
| 35 | Liver | Not measurable | Segment 4a liver mass | 10% | −30% | AST | 10% | 5% | -Improvement of anorexia, general weakness, and sleeping condition | ||
| segment 4b liver mass | 25% | −26% | ALT | 15% | 13% | ||||||
| Segment 5 liver mass | 34% | −57% | ALP | 12% | 0% | ||||||
| segment 6a liver mass | 60% | −77% | y-GT | 100% | −4% | ||||||
| segment 6b liver mass | 10% | −14% | CA19-9 | 51% | 21% | ||||||
| Segment 8 liver mass | 15% | −13% | CEA | 110% | 4% | ||||||
| 34 | Left breast wound | No mass | No mass | CA125 | 85% | 55% | -Reduction in discharge, bleeding, and area of left breast wound -Improvement of anorexia, general weakness, and sleeping condition |
||||
| CA15-3 | 70% | 25% | |||||||||
| CEA | 67% | 32% | |||||||||
| ESR | 40% | −46% | |||||||||
| CRP | 35% | −19% | |||||||||
| 36 | Liver | Not measurable | Left lobe liver mass | 37.50% | −10% | AST | 97% | −43% | -Reduction in pain and tenderness of right upper quadrant -Improvement of anorexia, general weakness, and sleeping condition |
||
| ALT | 107% | −43% | |||||||||
| ALP | 144% | −31% | |||||||||
| y-GT | 57% | −29% | |||||||||
| CA19-9 | 116% | 21% | |||||||||
| CEA | 6% | 59% | |||||||||
| 17 | Lungs | Not measurable | Lung nodules | stable | stable | ESR | 50% | 31% | -No clinical changes | ||
| CRP | 50% | 778% | |||||||||
| 39 | Right breast mastectomy site | Not measurable | Just blood exam has been done | CA125 | 70% | 49% | -Reduction in pain of right breast -Improvement of anorexia, general weakness, and sleeping condition |
||||
| CA15-3 | 65% | 33% | |||||||||
| CEA | 10% | 0% | |||||||||
| 30 | Right eyeball | Just microscopic investigation has been done | Just microscopic investigation has been done | ESR | 40% | −55% | -Reduction of angiogenesis and abnormal cells in cancerous site -Improvement of anorexia, general weakness, and sleeping condition |
||||
| CRP | 0% | 0% | |||||||||
| 15 | Excluded from the study | ||||||||||
| 32 | Excluded from the study | ||||||||||
| 23 | Excluded from the study | ||||||||||
| 21 | Excluded from the study | ||||||||||
| 38 | Excluded from the study | ||||||||||
Red color: The primary and secondary values are out of the normal range.
Blue color: The primary and secondary values are in the normal range.
Green color: The primary value is out of the normal range, and the second value is normal.
Orange color: The primary value is in the normal range, and the second value is out of the normal range.